疾病领域 | 数量 |
---|---|
肿瘤 | 1 |
排名前五的药物类型 | 数量 |
---|---|
小分子化药 | 1 |
排名前五的靶点 | 数量 |
---|---|
Tubulin(微管蛋白) | 1 |
靶点 |
作用机制 微管蛋白抑制剂 |
在研适应症 |
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
开始日期2020-05-29 |
申办/合作机构 |
开始日期2015-07-24 |
申办/合作机构 |
开始日期2012-02-23 |
申办/合作机构 |
Previously, abobotulinumtoxinA (aboBoNT-A) injected intraoperatively using intradermal (ID) route was shown to result in effective, but delayed post-surgical analgesia in pigs. Here, we explore the efficacy of preemptively administered aboBoNT-A in intact animals on pain and associated anxiety/depression-like reactivity following a surgery on the lower back of pigs. AboBoNT-A (200 U/animal) or saline, distributed across ten injection points, were injected around anticipated incision via ID route 15, 5, or 1 day before surgery (part A) or via ID, intramuscular (IM) or subcutaneous (SC) routes 15 days before surgery (part B). Animals were assessed for mechanical sensitivity, distress behaviors, and latency to approach the investigator before and after surgery for 7 days. AboBoNT-A, injected ID 15 days before surgery, didn’t alter any baseline behaviors, but largely prevented the onset of post-surgical allodynia, distress and normalized approaching behavior. Injections made 5 days before surgery led to similar analgesic responses, while those made 1 day before surgery were less effective. IM or SC injections of aboBoNT-A were ineffective. Thus, aboBoNT-A administered ID between 15 and 5 days before surgery represents the most optimal conditions for postoperative analgesia. These findings warrant for clinical investigation of analgesic efficacy of preemptively administered aboBoNT-A in postsurgical pain.
药物(靶点) | 适应症 | 全球最高研发状态 |
---|---|---|
STX140 ( Tubulin ) | 乳腺癌 更多 | 临床前 |